Comparative Pharmacology
Head-to-head clinical analysis: FEBUXOSTAT versus ZYLOPRIM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FEBUXOSTAT versus ZYLOPRIM.
FEBUXOSTAT vs ZYLOPRIM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Febuxostat is a non-purine selective inhibitor of xanthine oxidase (XO). It inhibits both oxidized and reduced forms of XO, thereby reducing the conversion of hypoxanthine to xanthine and xanthine to uric acid, leading to decreased serum uric acid levels.
Allopurinol is a xanthine oxidase inhibitor that reduces the production of uric acid by inhibiting the conversion of hypoxanthine to xanthine and xanthine to uric acid.
40 mg orally once daily; may increase to 80 mg orally once daily if serum urate goal not achieved after 2 weeks.
100-300 mg orally once daily, maximum 800 mg/day.
None Documented
None Documented
Terminal elimination half-life: 5-8 hours in healthy subjects; prolonged in renal impairment (e.g., up to 9.6 hours in moderate impairment). Clinical context: dosing interval is once daily, consistent with half-life.
Clinical Note
moderateFebuxostat + Theophylline
"The serum concentration of the active metabolites of Theophylline can be increased when Theophylline is used in combination with Febuxostat."
Clinical Note
moderateFebuxostat + Aminophylline
"The serum concentration of the active metabolites of Aminophylline can be increased when Aminophylline is used in combination with Febuxostat."
Clinical Note
moderateFebuxostat + Dyphylline
"The serum concentration of the active metabolites of Dyphylline can be increased when Dyphylline is used in combination with Febuxostat."
Clinical Note
moderateAllopurinol: 1-2 hours; oxypurinol: 18-30 hours (prolonged to 48-72 hours in renal impairment). Clinical context: oxypurinol half-life determines dosing interval; dose adjustment required for CrCl < 20 mL/min.
Renal: 1-3% unchanged; biliary/fecal: ~50% as metabolites (acyl glucuronides, oxidative metabolites); other: ~49% metabolized and eliminated via multiple pathways including biliary and direct intestinal excretion of unchanged drug.
Renal: allopurinol ~10% unchanged, oxypurinol ~70% unchanged; total renal elimination ~76% (allopurinol + oxypurinol); fecal/biliary: minor (~12-20% as allopurinol, ~3-5% as oxypurinol).
Category C
Category C
Xanthine Oxidase Inhibitor
Xanthine Oxidase Inhibitor
Azathioprine + Febuxostat
"The serum concentration of Febuxostat can be increased when it is combined with Azathioprine."